Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile

PHASE2CompletedINTERVENTIONAL
Enrollment

551

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
COVID-19Vaccines
Interventions
BIOLOGICAL

CoronaVac®

The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.

BIOLOGICAL

Omicron Vaccine

"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."

BIOLOGICAL

Trivalent Vaccine

"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."

Trial Locations (3)

Unknown

Universidad del Desarrollo - Clínica Alemana, Santiago

Pontificia Universidad Católica - Marcoleta Center, Santiago

Universidad San Sebastián, Santiago

All Listed Sponsors
collaborator

Sinovac Life Sciences Co., Ltd.

INDUSTRY

lead

Pontificia Universidad Catolica de Chile

OTHER